62: Radioimmunotherapy in Lymphomas

Jul 8, 2016 by in ONCOLOGY Comments Off on 62: Radioimmunotherapy in Lymphomas

Radioimmunotherapy in Lymphomas Reem Karmali and Stephanie A. Gregory Rush University Medical Center/Rush University, Chicago, IL, USA Radioimmunotherapy (RIT) combines a radiation-emitting radionuclide with an anti-CD20 monoclonal antibody to treat…

read more

36: Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Jul 8, 2016 by in ONCOLOGY Comments Off on 36: Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte-Predominant Hodgkin Lymphoma Dennis A. Eichenauer University Hospital Cologne, Cologne, Germany and German Hodgkin Study Group (GHSG), Cologne, Germany Multiple Choice Questions 1.  Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical…

read more

57: Light-Chain Amyloidosis

Jul 8, 2016 by in ONCOLOGY Comments Off on 57: Light-Chain Amyloidosis

Light-Chain Amyloidosis David C. Seldin Boston University, Boston, MA, USA Case study 57.1 An 80-year-old man is referred to you for evaluation and treatment. The patient had been noted by…

read more

26: Primary Myelofibrosis

Jul 8, 2016 by in ONCOLOGY Comments Off on 26: Primary Myelofibrosis

Primary Myelofibrosis Ayalew Tefferi Mayo Clinic, Rochester, MN, USA Introduction Primary myelofibrosis (PMF) is listed under the World Health Organization (WHO) classification category of myeloproliferative neoplasms (MPNs). The operational subcategory…

read more

56: Treatment of Multiple Myeloma

Jul 8, 2016 by in ONCOLOGY Comments Off on 56: Treatment of Multiple Myeloma

Treatment of Multiple Myeloma Cindy Varga, Claudia Paba Prada, Kenneth Anderson, and Paul Richardson Dana-Farber Cancer Institute, Boston, MA, USA Prognostic Markers Introduction Multiple myeloma is a heterogeneous disease with…

read more

55: Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström’s Macroglobulinemia

Jul 8, 2016 by in ONCOLOGY Comments Off on 55: Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström’s Macroglobulinemia

Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström’s Macroglobulinemia Silvia Gentili1 and Sagar Lonial2 1Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy 2The Winship Cancer Institute of Emory…

read more

47: HIV-Associated Lymphoma

Jul 8, 2016 by in ONCOLOGY Comments Off on 47: HIV-Associated Lymphoma

HIV-Associated Lymphoma Kieron Dunleavy National Cancer Institute, Bethesda, MD, USA 1.  What are the most important etiological factors for the development of HIV-associated lymphoma? The pathogenesis of HIV-associated lymphoma is complex…

read more
Get Clinical Tree app for offline access